Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Liraglutide Market Size And Revenue Outlook Through 2030
The liraglutide market size has experienced significant growth in recent years. It is anticipated to expand from $6.88 billion in 2025 to $7.45 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.2%. This historical growth can be attributed to factors such as the increasing global prevalence of type 2 diabetes, the proven effectiveness of GLP-1 receptor agonists in clinical trials, the demand for therapies that address both glucose management and weight control, the approval of liraglutide for both diabetes and obesity indications, and the growing confidence among physicians in injectable incretin treatments.
The liraglutide market is projected to experience robust expansion over the coming years, reaching a valuation of $10.23 billion by 2030, driven by an impressive compound annual growth rate (CAGR) of 8.3%. This anticipated growth during the forecast period is fueled by several factors, including the escalating global prevalence of obesity, a growing inclination towards diabetes treatments that prioritize weight management, the expansion of initiatives for screening metabolic disorders, increasing patient demand for effective appetite-suppressing solutions, and ongoing advancements and public knowledge concerning GLP-1 based therapies. Key trends expected during this period encompass the significant integration of liraglutide in managing type 2 diabetes, its increasing application for medical weight management purposes, a broader acceptance of injectable GLP-1 therapies, the development of more extensive long-term programs for metabolic disease management, and an intensified emphasis on achieving the combined advantages of both blood sugar regulation and weight reduction.
Get A Free Sample Report With In-Depth Market Insights:
Liraglutide Market Growth Factors Behind Sustained Expansion
The rising number of individuals with diabetes is anticipated to fuel the expansion of the liraglutide market in the future. Diabetes is a long-term ailment characterized by the body’s inability to adequately manage blood sugar levels, stemming from either inadequate insulin production or inefficient utilization of insulin. The prevalence of diabetes is on the rise, attributed to elements like inactive lifestyles, poor dietary habits, and a global increase in obesity. Medications for diabetes, including liraglutide, function by imitating the effects of the GLP-1 hormone, thereby improving insulin secretion, reducing blood glucose levels, and encouraging weight reduction, which assists in managing type 2 diabetes. As an illustration, a report from the Government of the United Kingdom, an information website based in the UK, indicated that in March 2024, the percentage of individuals with type 1 diabetes in England who received all eight specified care processes at GP practices participating in the NDA rose to 43.8% in March 2023, up from 35.2% in the preceding year. Consequently, the expanding population affected by diabetes is propelling the growth of the liraglutide market.
Liraglutide Market Segment Trends And Revenue Contributors
The liraglutide market covered in this report is segmented –
1) By Brands: Victoza, Saxenda
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies And Drug Stores, Online Pharmacies
3) By Type Of Application: Diabetes Treatment, Weight Management
4) By End-Users: Hospitals And Clinics, Homecare Settings
Subsegments:
1) By Victoza: Type 2 Diabetes Treatment Or Weight Management
2) By Saxenda: Weight Loss Treatment Or Obesity Management
Liraglutide Market Industry Trends Fueling Future Revenue Growth
Key companies operating in the liraglutide market are innovating with new products, such as generic GLP-1, aiming to expand available treatment options and fulfill the market’s need for more affordable choices. Generic GLP-1 describes iterations of GLP-1 receptor agonists that are manufactured following the expiration of patent protection on the original branded medicines, thus presenting cost-effective alternatives for the management of conditions like type 2 diabetes and obesity. Illustratively, in June 2024, Teva Pharmaceutical Industries Ltd., a pharmaceutical company based in Israel, launched the first generic GLP-1, similar to Victoza, in the U.S. market, thereby catering to the growing demand for these therapies. Liraglutide injections are administered to improve blood sugar management in adults and children aged 10 and above who have type 2 diabetes, and additionally to decrease the risk of cardiovascular incidents in adults with type 2 diabetes and pre-existing cardiovascular conditions.
Liraglutide Market Competitive Landscape: Which Companies Lead The Industry?
Major companies operating in the liraglutide market are Novo Nordisk A/S
View The Full Liraglutide Market Report:
Liraglutide Market Global Footprint: Which Region Leads The Market?
North America was the largest region in the liraglutide market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the liraglutide market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
